Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹11,540 Cr
Revenue (TTM)
₹2,512 Cr
Net Profit (TTM)
₹544 Cr
ROE
18.9 %
ROCE
25.5 %
P/E Ratio
21.2
P/B Ratio
3.6
Industry P/E
33.39
EV/EBITDA
13.9
Div. Yield
0.5 %
Debt to Equity
0
Book Value
₹257.9
EPS
₹45.9
Face value
2
Shares outstanding
122,736,348
CFO
₹2,301.62 Cr
EBITDA
₹3,925.38 Cr
Net Profit
₹2,702.04 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alivus Life Sciences
| 0.8 | 2.8 | 2.7 | -13.3 | 31.5 | -- | -- |
|
BSE Healthcare
| -3.1 | -2.9 | -3.1 | 4.0 | 25.0 | 15.7 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Alivus Life Sciences
| -10.0 | 50.1 | 56.4 | -33.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alivus Life Sciences
|
924.0 | 11,539.7 | 2,512.3 | 543.7 | 28.3 | 19.3 | 21.2 | 3.6 |
| 349.5 | 3,112.8 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.4 | 2.1 | |
| 368.9 | 6,657.6 | 1,053.1 | 293.6 | 32.3 | 24.6 | 22.7 | 5.1 | |
| 1,131.2 | 11,940.9 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 1,510.4 | 29,049.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.4 | 5.8 | |
| 12,129.0 | 15,918.8 | 1,575.1 | 179.1 | 14.9 | 11.4 | 88.9 | 9.6 | |
| 1,851.1 | 3,162.1 | 673.7 | 202.6 | 17.6 | 19.4 | 15.6 | 5.5 | |
| 765.1 | 3,444.8 | 588.5 | 102.9 | 22.1 | 12.7 | 33.9 | 4.1 | |
| 603.0 | 7,003.9 | 502.0 | 138.7 | -- | 32.8 | 50.5 | 8.1 | |
| 136.0 | 3,636.7 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.5 |
IPO update: Glenmark Life Sciences
4 min read•By Danish Khanna
Glenmark Life Sciences IPO: Information analysis
6 min read•By Rajan Gulati and Arul Selvan
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan,... telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited. Read more
Incorporated
2011
Chairman
Hiren K Patel
Managing Director
Yasir Rawjee
Group
Glenmark
Headquarters
Solapur, Maharashtra
Website
Looking for more details about Alivus Life Sciences Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Alivus Life Sciences Ltd is ₹924.00 (NSE) and ₹925.00 (BSE) as of 19-Mar-2026 10:49 IST. Alivus Life Sciences Ltd has given a return of 31.52% in the last 3 years.
The P/E ratio of Alivus Life Sciences Ltd is 21.22 times as on 18-Mar-2026, a 36 discount to its peers’ median range of 33.39 times.
The P/B ratio of Alivus Life Sciences Ltd is 3.65 times as on 18-Mar-2026, a 69 premium to its peers’ median range of 2.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
27.24
|
4.71
|
|
2024
|
20.17
|
4.09
|
|
2023
|
10.28
|
2.25
|
|
2022
|
13.43
|
2.74
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Alivus Life Sciences Ltd are Rs 1,225.10 and Rs 819.00 as of 19-Mar-2026.
Alivus Life Sciences Ltd has a market capitalisation of ₹ 11,540 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Alivus Life Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-17.95
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.